The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Approaching frontline treatment selection and shared decision making in myeloma in the current era
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the evolving approach to treatment selection for newly diagnosed multiple myeloma (MM), emphasizing the importance of shared decision-making in this setting. Dr Schjesvold highlights the need to weigh up the benefits and risks of available treatment options, such as transplant versus non-transplant approaches for younger patients and the choice of quadruplet therapy with or without certain agents for elderly patients, considering factors like toxicity and individual patient preferences. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
